GMAB News and Press, Genmab A/S From 03/16/20

Today, we will see why Genmab (GMAB) is an attractive biotech pick in March 2020. Company overview Genmab is a dual-listed biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. The company was founded in 19...

International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 18th and 19th, 2020 Canada NewsWire NEW YORK, March 10, 2020 NEW YORK , March 10, 2020 /CNW/ - Deutsche Bank today announced the lineup for its Deposi...

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 02/13/2020. Please visit our Tracking Ole Andreas Halvorsen&#...

Drug regulators in the U.S. and EU have accepted Novartis ' (NYSE: NVS) applications to expand their approvals of ofatumumab to include patients with multiple sclerosis. The Food and Drug Administration is giving the marketing application a priority review, so a decision should come by this J...

Image source: The Motley Fool. Genmab A/S   (NASDAQ: GMAB) Q4 2019 Earnings Call Feb 19, 2020 , 12:00 p.m. ET Operator Continue reading

Genmab A/S (GNMSF) Q4 2019 Earnings Conference Call February 19, 2020 12:00 PM ET Company Participants Jan van de Winkel - Chief Executive Officer David Eatwell - Chief Financial Officer Anthony Pagano - American Senior Vice President, Finance & Corporate Development Confe...

The following slide deck was published by Genmab A/S in conjunction with their 2019 Q4 earnings Read more ...

Triggered by the achievement of $3B in global Darzalex (daratumumab) sales in 2019, Genmab A/S (NASDAQ: GMAB ) earns a $150M milestone payment from Johnson & Johnson (NYSE: JNJ ) unit Janssen Biotech. More news on: Genmab A/S, Johnson & Johnson, Healthcare stocks news, Stocks on ...

The following slide deck was published by Genmab A/S in conjunction with this Read more ...

The stock market and equity investors love growth. The ability of a company to grow revenues with strong momentum is typically a sign of a hot product or service in high demand that is capturing market share. Among the fastest growing companies, consideration for measures like profitability or...